3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
2
Recruiting
1
Enrolling by invitation
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
4
Dermatologic
2
Thoracic
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Conditions
Ovarian Neoplasms
508
Uterine Cervical Neoplasms
361
Endometrial Neoplasms
305
Breast Neoplasms
130
Colorectal Neoplasms
112
Neoplasms
98
Fallopian Tube Neoplasms
90
Carcinoma, Non-Small-Cell Lung
87
Stomach Neoplasms
83
Pancreatic Neoplasms
79
Lung Neoplasms
72
Melanoma
68
Prostatic Neoplasms
67
Carcinoma, Ovarian Epithelial
65
Neoplasm Metastasis
63
Triple Negative Breast Neoplasms
51
Vulvar Neoplasms
50
Squamous Cell Carcinoma of Head and Neck
49
Head and Neck Neoplasms
45
Esophageal Neoplasms
43
Uterine Neoplasms
40
Peritoneal Neoplasms
40
Urinary Bladder Neoplasms
38
Carcinoma, Hepatocellular
35
Carcinoma, Renal Cell
34
Uterine Cervical Dysplasia
31
Sarcoma
31
Papillomavirus Infections
31
Colonic Neoplasms
31
Recurrence
29
Interventions
pembrolizumab
1
Nivolumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Colitis, Ulcerative
×
Gynecologic
×
Clear all
NCT07223424
2026-04-16
PSI-Immune
University of Pittsburgh
Phase 2
Recruiting
880 enrolled